{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[9,2,9,3],[10,2,10,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910779533903321"]
[null,null,"Titolo",null,"Congestive heart failure [[electronic resource] ] : symptoms, causes and treatment / / Josias E. Garcia and Victoro R. Wright, editors"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Science Publishers, c2010"]
[null,null,"ISBN",null,"1-61761-958-2"]
[null,null,"Descrizione fisica",null,"1 online resource (244 p.)"]
[null,null,"Collana",null,"Cardiology research and clinical developments"]
[null,null,"Disciplina",null,"616.1/29"]
[null,null,"Soggetti",null,"Congestive heart failure"]
[{"$nulls":4},"Heart failure"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"CONGESTIVE HEART FAILURE: SYMPTOMS, CAUSES AND TREATMENT\"\"; \"\"CONGESTIVE HEART FAILURE: SYMPTOMS, CAUSES AND TREATMENT\"\"; \"\"CONTENTS\"\"; \"\"PREFACE\"\"; \"\"MONITORING PULMONARY EDEMA IN CHF PATIENTS WITH A HYBRID BIO-IMPEDANCE APPROACH\"\"; \"\"ABSTRACT\"\"; \"\"1. PULMONARY EDEMA IN CHF PATIENTS â€? ORIGINS AND MEASURING TECHNIQUES\"\"; \"\"2. THE BIO-IMPEDANCE APPROACH IN MEASURING PULMONARY EDEMA\"\"; \"\"3. A HYBRID BIO-IMPEDANCE SYSTEM FOR DIAGNOSING AND MONITORING CHF PATIENTS\"\"; \"\"3.1. Technical Design\"\"; \"\"3.1.1. Hardware design\"\"; \"\"3.1.2. Software design\"\"; \"\"Lung resistivity estimation\"\""]
[{"$nulls":4},"\"\"RR and QT interval calculation\"\"\"\"3.2. Clinical Results\"\"; \"\"3.2.1. Baseline measurements\"\"; \"\"3.2.2. CHF patientsâ€? classification and long-term monitoring\"\"; \"\"3.2.3. Monitoring CHF patients under intravenous diuretics treatment\"\"; \"\"3.2.4. Correlation between bio-impedance measurements and X-ray radiographs\"\"; \"\"3.3. Monitoring CHF Patients at Home Via a Telemedicine Approach\"\"; \"\"4. SUMMARY AND CONCLUSIONS\"\"; \"\"REFERENCES\"\"; \"\"THE ASSOCIATION BETWEEN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SHOCKS AND HEART FAILURE: A REVIEW OF PATHOGENESIS AND MANAGEMENT\"\"; \"\"ABSTRACT\"\""]
[{"$nulls":4},"\"\"1. MADIT II AND SCD-HEFT: TWO MAJOR RANDOMIZED CONTROLLED TRIALS OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY\"\"\"\"2. PATHOGENESIS OF HEART FAILURE IN PATIENTS WITH ICD SHOCKS\"\"; \"\"The Effect of Shock: Appropriate and Inappropriate Shocks\"\"; \"\"ICD Shocks and the Activation of Sympathetic Nervous System\"\"; \"\"The Activation of Sympathetic Nervous System and the Psychiatric "]
[{"$nulls":4},"Consequences: Impact on Heart Failure Progression\"\"; \"\"MANAGEMENT\"\"; \"\"Patient Selection\"\"; \"\"Optimal Medical Management of Heart Failure\"\"; \"\"Device Programming\"\"; \"\"Anti-Arrhythmic Medications, Including Amiodarone\"\""]
[{"$nulls":4},"\"\"Management of Psychiatric Symptoms and Syndromes\"\"\"\"Organized Protocol for Review of Patients Receiving ICD Shocks\"\"; \"\"CONCLUSION\"\"; \"\"REFERENCES\"\"; \"\"REVERSIBLE LEFT VENTRICULAR DYSFUNCTION: THE TAKOTSUBO SYNDROME\"\"; \"\"ABSTRACT\"\"; \"\"INTRODUCTION\"\"; \"\"Epidemiology\"\"; \"\"Aetiology\"\"; \"\"Clinical Features\"\"; \"\"Diagnosis\"\"; \"\"Laboratory Data\"\"; \"\"Cardiac Biomarkers\"\"; \"\"Stress Hormones\"\"; \"\"Electrocardiography\"\"; \"\"Echocardiography\"\"; \"\"Coronary Angiography and Ventriculography\"\"; \"\"Cardiovascular magnetic resonance imaging\"\"; \"\"Myocardial Single Photon Emission Computed Tomography\"\""]
[{"$nulls":4},"\"\"Endomyocardial Biopsies\"\"\"\"Pathophysiological Mechanisms\"\"; \"\"Multivessel Epicardial Coronary Artery Spasm\"\"; \"\"Coronary Microvascular Impairment\"\"; \"\"Catecholamine Cardiotoxicity\"\"; \"\"Therepeutic Options\"\"; \"\"Prognosis\"\"; \"\"CONCLUSION\"\"; \"\"REFERENCES\"\"; \"\"OXIDATIVE STRESS AND HEART FAILURE: STILL A VIABLE THERAPEUTIC TARGET?\"\"; \"\"ABSTRACT\"\"; \"\"INTRODUCTION\"\"; \"\"SOURCES OF OXIDATIVE STRESS IN HEART FAILURE\"\"; \"\"PHYSIOLOGICAL IMPORTANCE OF REDOX SIGNALING\"\"; \"\"IMPLICATIONS FOR STEM CELL THERAPY\"\"; \"\"REDOX-SMART DRUG DESIGN FOR HEART FAILURE\"\"; \"\"CONCLUSION AND PERSPECTIVES\"\""]
[{"$nulls":4},"\"\"ACKNOWLEDGEMENT\"\""]